Pyxis Oncology, Inc. (PYXS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Pyxis Oncology reported revenue of $13.9M, down 14.2% from $16.1M the year before. Net income was -$79.6M (a -574.5% net margin), or -$1.28 per diluted share. Gross margin was 82.8% and operating margin was -609.2%. Operating activities generated -$63.5M of cash, leaving -$63.5M of free cash flow. At fiscal year end, Pyxis Oncology held $91.5M in total assets against $38.1M in total liabilities, including $15.4M of cash and equivalents.
Open the full interactive Pyxis Oncology financials → Quarterly statements, key ratios, valuation history and price charts.
Pyxis Oncology Key Stats
| Share Price | $1.85 |
|---|---|
| Market Cap | $118.4M |
| Revenue YoY Growth | -14.2% |
| 52-Week Range | $1.06 – $5.34 |
| Shares Outstanding | 64.0 million (basic, 2026 Q2) |
Pyxis Oncology Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $16.1M | $13.9M |
| Gross Profit | — | — | — | $15.7M | $11.5M |
| Operating Income | -$69.7M | -$123.5M | -$82.2M | -$89.5M | -$84.4M |
| Pre-Tax Income | -$76.0M | -$120.7M | -$73.8M | -$79.5M | -$78.2M |
| Income Tax | — | — | — | -$2.2M | $1.4M |
| Net Income | -$76.0M | -$120.7M | -$73.8M | -$77.3M | -$79.6M |
| Diluted EPS | -$8.95 | -$3.65 | -$1.85 | -$1.32 | -$1.28 |
Pyxis Oncology Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $11.0M | $0 | $0 |
| Net Income | -$22.0M | -$18.1M | -$23.3M | -$25.3M |
| Diluted EPS | -$0.35 | -$0.29 | -$0.37 | -$0.40 |
Pyxis Oncology Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $274.7M | $179.3M | $9.7M | $19.5M | $15.4M |
| Current Assets | $278.7M | $186.6M | $124.6M | $132.4M | $72.1M |
| Total Assets | $280.0M | $211.4M | $173.7M | $157.2M | $91.5M |
| Current Liabilities | $18.7M | $31.6M | $25.8M | $17.7M | $21.1M |
| Total Liabilities | $18.7M | $50.6M | $48.0M | $36.4M | $38.1M |
| Shareholders' Equity | $261.3M | $160.8M | $125.7M | $120.8M | $53.4M |
Pyxis Oncology Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$35.3M | -$89.3M | -$70.7M | -$57.7M | -$63.5M |
| Cash From Investing | -$590,000 | -$6.4M | -$104.8M | $8.2M | $58.9M |
| Cash From Financing | $304.0M | $183,000 | $5.9M | $59.3M | $594,000 |
| Free Cash Flow | -$35.9M | -$95.7M | -$77.4M | -$57.9M | -$63.5M |
Figures from Pyxis Oncology's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Pyxis Oncology financials page for every line item.
Pyxis Oncology Company Profile
| Ticker | PYXS |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001782223 |
Frequently Asked Questions
What was Pyxis Oncology's revenue in fiscal 2025?
Pyxis Oncology (PYXS) reported revenue of $13.9M for fiscal 2025.
What is Pyxis Oncology's annual revenue history?
Pyxis Oncology's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $16.1M; 2025: $13.9M.
What was Pyxis Oncology's net income in fiscal 2025?
Pyxis Oncology reported net income of -$79.6M for fiscal 2025.
What was Pyxis Oncology's earnings per share (EPS) in fiscal 2025?
Pyxis Oncology's diluted EPS was -$1.28 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Pyxis Oncology generate in fiscal 2025?
Pyxis Oncology generated -$63.5M of free cash flow in fiscal 2025.
What was Pyxis Oncology's revenue last quarter?
In its most recent reported quarter (2026 Q2), Pyxis Oncology reported revenue of $0.
How many shares of Pyxis Oncology are outstanding?
Pyxis Oncology reported a weighted average of 64.0 million basic shares outstanding in 2026 Q2.
What is Pyxis Oncology's market cap?
Based on its latest closing price, Pyxis Oncology (PYXS) has a market capitalization of about $118.4M.
When does Pyxis Oncology's fiscal year end?
Pyxis Oncology's fiscal year end, as registered with the SEC, is December 31.
Where is Pyxis Oncology headquartered?
Pyxis Oncology lists its business address in Boston, Massachusetts in its SEC filings.